[HTML][HTML] Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly …
J Zhang, Z Zou, J Tan, J Shi, H Yang, H Wang… - Journal of …, 2023 - ncbi.nlm.nih.gov
Abstract Background and Objective: Immune checkpoint inhibitors (ICIs) combined with
angiogenesis inhibitors may have synergistic effects in elderly patients with advanced driver …
angiogenesis inhibitors may have synergistic effects in elderly patients with advanced driver …
Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer
Q Gao, S Tang, H Chen, H Chen, XJ Li, YQ Jiang… - Drug …, 2020 - Taylor & Francis
This study was conducted to determine the antitumor effects and ability of an anlotinib (AL)
hydrogel (AL–HA–Tyr) to reduce toxicity in a mouse model of Lewis lung cancer (LLC). We …
hydrogel (AL–HA–Tyr) to reduce toxicity in a mouse model of Lewis lung cancer (LLC). We …
Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
M Tang, C Song, Y Zhang, X Xu, C Wang… - Lipids in Health and …, 2021 - Springer
Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third
or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from …
or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from …
Anlotinib exerts anti-cancer effects on KRAS-mutated lung cancer cell through suppressing the MEK/ERK pathway
H Hu, Y Liu, S Tan, XX Xie, J He, F Luo… - Cancer Management …, 2020 - Taylor & Francis
Background With a high frequency of 30%, KRAS mutations in patients with non-small cell
lung cancer (NSCLC) often lead to their poor response to most anti-cancer therapies. As a …
lung cancer (NSCLC) often lead to their poor response to most anti-cancer therapies. As a …
[HTML][HTML] Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling
X Zhang, Y Zhang, Y Jia, T Qin, C Zhang… - Cancer Biology & …, 2020 - ncbi.nlm.nih.gov
Objective: Bevacizumab is a recombinant humanized monoclonal antibody that blocks
vascular endothelial growth factor (VEGF) with clear clinical benefits. However, overall …
vascular endothelial growth factor (VEGF) with clear clinical benefits. However, overall …
A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second-or third-line salvage treatment for advanced non-small cell lung …
H Wang, J Chu, Y Zhao, H Tang, L Wang… - Cancer Management …, 2020 - Taylor & Francis
Purpose Anlotinib is a newly developed oral multitarget tyrosine kinase inhibitor. We
retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with …
retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with …
Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer: a real-world study
Q Zhong, Z Liu - Cancer Management and Research, 2021 - Taylor & Francis
Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …
Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules)+ oxaliplatin) in treating stage IV gastric cancer: study protocol for a …
J Wang, DX Wu, L Meng, G Ji - BMJ open, 2020 - bmjopen.bmj.com
Introduction Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that
targets angiogenesis-related kinases and has already showed good safety and efficacy in …
targets angiogenesis-related kinases and has already showed good safety and efficacy in …
5-(3, 4, 5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in …
Z Bai, X Liu, Q Guan, N Ding, Q Wei, M Zhao… - Chemico-Biological …, 2020 - Elsevier
Colorectal cancer (CRC) is one of the most common malignancies, and multidrug resistance
(MDR) reduces the efficiency of anticancer drugs. Therefore, the development of novel …
(MDR) reduces the efficiency of anticancer drugs. Therefore, the development of novel …
Genetic polymorphisms in cyp2c19 cause changes in plasma levels and adverse reactions to anlotinib in chinese patients with lung cancer
T Tan, G Han, Z Cheng, J Jiang, L Zhang… - Frontiers in …, 2022 - frontiersin.org
Background: Anlotinib is a small molecular multi-targeting tyrosine kinase inhibitor. Growing
evidence indicates that treatment efficacy, and toxicity varies considerably between …
evidence indicates that treatment efficacy, and toxicity varies considerably between …